Revolutionizing Dupilumab Treatment in Refractory Eosinophilic Cellulitis: A Case Report and Comprehensive Literature Review

Eosinophilic cellulitis (EC) or Wells' syndrome, characterized by its rarity and diverse clinical presentations, presents substantial challenges in diagnosis and treatment. This case study details the challenging journey of a 48-year-old woman with non-specific skin lesions, showcasing the persistence of dermatitis despite exhaustive attempts at various interventions outlined in the literature. In the absence of a consensus on optimal management for EC, this study introduces a transformative solution through the utilization of dupilumab, a monoclonal antibody targeting interleukin-4/interleukin-13. The patient experienced marked improvement and resolution of dermatitis following dupilumab treatment alone, highlighting the efficacy of this targeted immunomodulatory approach in cases refractory to traditional therapies. This pioneering case underscores the significance of exploring innovative treatments and suggests dupilumab as a potential breakthrough therapeutic option in addressing EC refractory to standard medical management.